BCMAがなくても問題なし：CD70標的CAR-NK細胞がハイリスク骨髄腫に有望性を示す
Don M Benson1, Michael A Caligiuri2
1Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Blood cancer discovery
|December 19, 2025
Abstract:
Despite recent advances, multiple myeloma remains essentially incurable for most patients, particularly those with high-risk cytogenetics and those whose disease relapses after BCMA-targeting therapies. A novel CD27 CAR_sIL15 NK cell targeting CD70 may offer new hope in this area of urgent, unmet medical need. See related article by Lin et al., p. XX .
